RESEARCH ARTICLE

Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study [version 1; peer review: 1 approved, 2 approved with reservations]

Eva Musdalita1,2, Rudy Hidayat1, Sumariyono Sumariyono1, Suryo Anggoro Kusumo Wibowo1, Anna Ariane1, Hamzah Shatri3, Iris Rengganis4, Dono Antono5

1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/ Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
2Department of Internal Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
3Division of Psychosomatic and Palliative Care, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
4Division of Allergy and Immunology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia
5Division of Cardiovascular, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

Abstract

Background: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, characterized by systemic inflammation, joint destruction and disability. Methotrexate (MTX) is used as the primary treatment for RA patients. However, the response to MTX therapy is highly varied and difficult to predict. This study sought to determine the role of MTX by measuring the MTX polyglutamate 3 (MTX-PG3) levels and the disease activity score 28 based on C-reactive protein (DAS28-CRP) of RA patients.

Method: A prospective cohort study was conducted at the Rheumatology Polyclinic of Dr. Cipto Mangunkusumo General Hospital. Thirty-four patients with RA were included and followed up to 12 weeks. The RA patients were treated with MTX 10 mg per week and an increased dose of 5 mg per week every month. DAS28-CRP and MTX-PG3 level were assessed at week 8 and 12. Multivariate logistic regression analysis was used to determine the correlation between MTX-PG3 and DAS28-CRP.

Result: A total of 34 RA patients were followed and the MTX was well tolerated in which no increase of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT)
and glomerular filtration rate (GFR) were observed. The mean scores of DAS28-CRP decreased following the MTX-treatment: 3.93, 3.22 and 2.82 at week 0, 8 and 12, respectively. In contrast, the median concentration of MTX-PG3 increased from week 8 to week 12 followed by increasing the dose of MTX. Our analysis suggested there was a moderate positive correlation between MTX-PG3 levels and DAS28-CRP score at week 8 and week 12 post-MTX treatment.

**Conclusion:** The level of MTX-PG3 is correlated with DAS28-CRP score suggesting that MTX-PG3 could be used as an indicator to assess the disease activity in RA patients. Nevertheless, a prospective study with a higher number of patients is needed to confirm this finding.

**Keywords**
Rheumatoid arthritis, MTX-PG3 level, disease activity, DAS28-CRP, methotrexate
Introduction

Methotrexate (MTX) is the first-line drug to treat rheumatoid arthritis (RA) which provides higher survival rate than other disease modifying arthritis rheumatoid drugs (DMARD) and is recommended by the European League Against Rheumatism and the American College of Rheumatology. MTX has become a commonly used treatment option because it is a cost-effective and has acceptable safety profile.1–3 Although MTX is the main RA therapy and most patients show symptomatic improvement and have acceptable side effects, the response to MTX therapy is highly varied and difficult to predict.4

MTX is transported into cells via the reduced folate carrier pathway and activated by polyglutamate synthase to methotrexate polyglutamate (MTX-PG).5 MTX-PG then inhibits the target enzymes such as thymidylate synthetase, dihydrofolate reductase and key enzymes for de novo purine synthesis pathway.6 Depending on the number of conjugated glutamates, MTX-PG may be present as MTX-PG1-5 or the longer chain MTX-PG (MTX-PG3-5) which is considered to be more active. MTX-PG3 is the most dominant and stable type of MTX-PG and could reflect the overall polyglutamate status.7 Therapeutic effects of MTX on RA patients depends on conversion of MTX to MTX-PG and therefore intracellular measurement of MTX-PG has been proposed as an objective method of guiding MTX therapy.8

Studies have been conducted to analyze the pharmacodynamics of MTX-PG, in particular MTX-PG3, since it is expected to be used to monitor the safety and effectiveness of MTX therapy in RA patients.8,9 A prospective cohort study found that MTX-PG3 and total MTX-PG levels were associated with decreased disease activity score 28 (DAS28) as measured at 3, 6, and 12 weeks. MTX-PG3 levels also positively correlated with the number of MTX dose during the treatment.9 However, studies showed different results in which the levels of MTX-PG3 had no potential as a marker of clinical improvement in RA patients, and also there was no significant relationship between MTX-PG level with the side effects and treatment response status.10,11 Therefore, the MTX-PG concentration in erythrocytes as a predictor of response to MTX therapy in RA patients is still a conflict. Besides that, the cut-off value for MTX-PG levels is different in each country since RA is determined by specific genetic factors.12 This prospective study aimed to clarify the relationship between intra erythrocytic MTX-PG3 concentration and DAS28 based on C-reactive protein (DAS28-CRP) in Indonesia. The CRP value is considered more sensitive than short-term changes in RA disease activity.13 This study was expected to provide a better understanding of the role of MTX-PG3 in the treatment of RA.

Methods

Study design and patients

A prospective cohort study was conducted among RA patients treated at Rheumatology Polyclinic of Dr. Cipto Mangunkusumo General Hospital (RSCM) in Jakarta. The RA patient was diagnosed based on the 2010 American College of Rheumatology/European League Against Rheumatism (2010 ACR/EULAR) diagnostic criteria which is a new and more sensitive approach in diagnosing RA. The diagnostic criteria of 2010 ACR/EULAR includes joint involvement, serological test, CRP, erythrocyte sedimentation rate (ESR), and duration of symptoms.14 Before MTX treatment, DAS28-CRP was assessed, demographic and clinical data were collected including gender, age, body mass index (BMI), CRP, nonsteroidal anti-inflammatory drugs (NSAID) use, steroid use, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), glomerular filtration rate (GFR) and erythrocyte sedimentation rate (ESR). Subsequently, the patients were treated with MTX and were followed until 12 weeks post-treatment. The DAS28-CRP examination and the concentration of MTX-PG3 were re-assessed at week 8 and 12.

MTX treatment and follow-up

The patients received MTX therapy with an initial dose of 10 mg/week and an increased dose of 5 mg/week every month according to the degree of disease activity. The patients also received methylprednisolone 4 mg twice daily and omeprazole 20 mg once daily. At week 8 and 12, the venous blood was collected at least 1.5 hours after MTX administrated.

DAS28-CRP assessment

The DAS28-CRP assessment was conducted before the MTX treatment and during the follow-up of 8 and 12 weeks post-treatment. DAS28-CRP assesses 28 tender and swollen joint counts, general health and the level of CRP (mg/L) and the score was calculated based on formula that have been provided elsewhere.15 The DAS28-CRP score interpretation are as follows: <2.6: disease remission, 2.6–3.2: low disease activity, <3.2–5.1: moderate disease activity, and >5.1: high disease activity.16

MTX-PG3 measurement

To measure the MTX-PG3, the blood samples were first centrifuged for 5 min at 3000 rpm.17 The level of MTX-PG3 was measured using chromatographic analysis by injecting 10 μL of sample into Waters™ ACQUITY UPLC BEH C18
column (Waters Corporation, Milford, MA, USA) with mobile phase of 10 mM ammonium bicarbonate at pH 10, ammonium hydroxide, and methanol. The rate was maintained at 0.3 mL/min and analysis was conducted using the program of 0-0.5 min isocratic hold 5% B, 0.5-4 min linear gradient 5-40% B; 4.0-4.25 min linear gradient 4-100% B; 4.25-4.75 min isocratic 95% B; 4.75-5 min linear gradient 100-5% B; and 5-6 min 5% isocratic.

**Statistical analysis**

Descriptive analysis was performed to provide the distribution of the data. The MTX-PG3 levels and DAS28-CRP score were presented as mean ± standard deviation if the data normally distributed otherwise as median (min-max). At univariate analysis, Spearman’s correlation test was used to assess the correlation between the potential confounding variables with DAS28-CRP. The multivariate linear regression test was used to determine the correlation between the MTX-PG3 levels and DAS28-CRP scores by controlling for confounding variables. All analyses were conducted using SPSS software version 24 (SPSS Inc., Chicago, IL, USA, RRID:SCR_002865).

**Results**

**Patients’ characteristics**

A total of 34 RA patients were enrolled and analyzed, and the characteristics of the patients are presented in Table 1. No patients dropped out from the follow-up. Most of the patients (94.1%, 32/34) were female with an age range of 20 to 70 years. The mean BMI was 23.29 kg/m², indicating that most of the patients were in the ideal weight range. All patients did not smoke and had no comorbidities. Examination of SGOT, SGPT, and GFR showed normal limits with medians of 18 U/L, 18 U/L, and 102.5 mL/min/1.73m², respectively. The median of disease duration was 8.5 months.

The mean score of DAS28-CRP before the MTX treatment was 3.93 indicating most of the patients had a moderate disease activity state, then the DAS28-CRP scores decreased to 3.22 and 2.82 at week 8 and 12, respectively. The data of

| Characteristics               | Mean (SD)       |
|-------------------------------|-----------------|
| Age (year), median (min-max)  | 48 (20–70)      |
| Gender (n, %)                 |                 |
| Male                          | 2 (5.9)         |
| Female                        | 32 (94.1)       |
| Body mass index (kg/m²)       | 23.26 (0.73)    |
| Current smoker (n, %)         | 0 (0)           |
| Comorbid, (n, %)              | 0 (0)           |
| GFR (mL/min/1.73m²)           | 102.5 (3.5)     |
| SGOT (U/L), median (min-max)  | 18 (10–120)     |
| SGPT (U/L), median (min-max)  | 18 (9–61)       |
| CRP (mg/L), median (min-max)  | 3.0 (0.1–28.01) |
| Number of joints, median (min-max) | 9 (9–23) |
| Disease duration (month), median (min-max) | 8.5 (7–13) |
| DAS28-CRP                     |                 |
| Week 0                        | 3.93 (0.137)    |
| Week 8                        | 3.22 (0.148)    |
| Week 12                       | 2.82 (0.165)    |
| ΔDAS28-CRP                    |                 |
| Week 0-8                      | 0.54 (0.063)    |
| Week 8-12                     | 1.03 (0.071)    |
| MTX-PG3 (nmol/L)              |                 |
| Week 8 Median (min-max)       | 12.63 (1.33–81.30) |
| Week 12 Median (min-max)      | 42.67 (4.59–156.35) |
MTX-PG3 levels were not normally distributed with median at week 8 and 12 being 12.63 nmol/L and 42.67 nmol/L, respectively.

Correlation between MTX-PG3 and DAS28-CRP
A linear regression was used to identify the correlation of MTX-PG3 with DAS28-CRP and the changes of DAS28-CRP score (ΔDAS28-CRP). To do this, the confounding variables were first assessed including BMI, age, GFR, MTX dose, duration of disease, methylprednisolone dose, and number of joints affected through the Spearman’s correlation test. This analysis suggested that disease duration, methylprednisolone dose, and number of joints were potential confounding variables and therefore adjusted for further analysis (Table 2).

The multivariate analysis of the role of MTX-PG3 on DAS28-CRP with a linear regression are provided in Table 3. There was a significant correlation between MTX-PG3 levels and DAS28-CRP score at week 8 and 12 post-MTX treatment after adjusted all confounding variables, r=0.517 with p=0.022 and r=0.538 with p=0.013, respectively. Our analyses also suggested that there were significant correlations between the level of MTX-PG3 and the changes of DAS28-CRP scores (ΔDAS28-CRP) at week 8 and 12 post-MTX treatment (r=0.933 and r=0.787, respectively with p<0.001 for both) (Table 3).

Receiver Operating Characteristics (ROC) analysis
ROC analysis was conducted using ROC curve to determine how sensitive and specific the MTX-PG3 level was to predict the disease activity of RA. Data from 12 weeks post-treatment suggested that the cut-off value of MTX-PG3 level 78.4 nmol/L was able to reduce the DAS28-CRP score by more than 1.2 times. The area under the curve (AUC) was 0.9 (95% confidence interval 0.81–1, p=0.001) with a sensitivity of 75% and a specificity of 91% (Figure 1).

Discussion
In this study, we treated the RA patients with 10 mg MTX as an initial dose followed by an increase of 5 mg MTX/week, every month. A previous study found that treatment with an initial dose of at least 10 mg/week for the first three months with an increase of at least 20 mg/week for six months gave an excellent clinical response. Our data suggested that by increasing the MTX dose the MTX-PG3 level could increase by 70.4% from week 8 to week 12. In contrast, the DAS28-CRP score decreased from 3.93 (first week) to 3.93 at week 12, indicating that the disease activity changed from moderate to low degree. Based on the changes of DAS28-CRP scores, the response of the treatment was categorized as moderate response. In this study, MTX dose and MTX-PG3 levels were well tolerated since no adverse events presented at week 8 or 12, as indicated by no increase in the levels of SGOT, SGPT and GFR reported.

### Table 2. Spearman’s correlation showing the potential confounding variables associated with DAS28-CRP.

| Variable                        | DAS28-CRP at week 8 | DAS28-CRP at week 12 |
|---------------------------------|---------------------|----------------------|
|                                 | r       | p-value | r       | p-value |
| Disease duration                | 0.299   | 0.930   | 0.218   | 0.231   |
| Methylprednisolone dose at week 8 | 0.564   | 0.001   | 0.336   | 0.060   |
| Methylprednisolone dose at week 12| 0.287   | 0.111   | 0.456   | 0.007   |
| The number of joints involved   | 0.351   | 0.042   | 0.307   | 0.087   |

r: Spearman’s correlation coefficient.

### Table 3. Multivariate analysis showing the correlation of MTX-PG3 level with DAS28-CRP and ΔDAS28-CRP.

| Variable                        | Crude $R^2$ | Adjusted $R^2$ | p-value |
|---------------------------------|-------------|----------------|---------|
| DAS28-CRP                       |             |                |         |
| MTX-PG3 at week 8               | 0.719       | 0.517          | 0.022   |
| MTX-PG3 at week 12              | 0.734       | 0.538          | 0.013   |
| ΔDAS28-CRP                      |             |                |         |
| MTX-PG3 at week 8               | 0.966       | 0.933          | <0.001  |
| MTX-PG3 at week 12              | 0.935       | 0.787          | <0.001  |

$R^2$: Coefficient of determination.
Our data suggested that the levels of MTX-PG3 were correlated with DAS28-CRP score at week 8 and 12 post-MTX treatment. The same results were also observed between MTX-PG3 and $\Delta$DAS28-CRP. These suggested that the higher MTX-PG3 levels the higher the score of DAS28-CRP (i.e., the better the disease activity). These results are similar to a study in Japanese patients in which there was a significant association between MTX-PG3 level and DAS28 score from week 8 to 24 post-MTX therapy.\textsuperscript{17} The decrease in DAS28-CRP may occur in the folate reduction pathway through dihydrofolate reductase (DHFR) inhibition. Reduced DHFR activity interferes with homocysteine conversion to methionine and causes inhibition of immunoglobulin and rheumatoid factor inducers.\textsuperscript{20–22}

Further analysis using the ROC curve showed that MTX-PG3 level of 78.4 nmol/L at 12 weeks post-MTX treatment could predict a good response of the MTX treatment. A previous study reported that the cut-off level of MTX-PG at week 12 was more than 74 nmol/L to reduce DAS28 score and categorized as a moderate/good response.\textsuperscript{9}

There are some limitations of this study. The number of the patients included in this study were relatively small and a further study with a larger sample size and longer follow-up time is required. It should be noted that the correlation of the MTX-PG3 level with DAS28-CRP score and $\Delta$DAS28-CRP was influenced by confounding variables including duration of disease, methylprednisolone dose, and number of joints involved. Confounding factors are the main concern in the observational cohort study since no randomization was conducted.\textsuperscript{23} Nevertheless, we have tried to minimize the bias by adjusting those co-founding in the final analysis. In addition, several studies have shown that genetic factors play a role in the variability of treatment of each patient, in particular variations on gene encoding enzymes in the folate metabolism pathway.\textsuperscript{5,24} In this study, genetic factors were not controlled and could be the source of bias.

**Conclusion**

Our study suggests a moderate positive correlation between MTX-PG3 level and DAS28-CRP score in RA patients after 8 and 12 weeks post-MTX treatment. This indicates that level of MTX-PG3 may potentially be used to predict the degree of RA disease activity and as an indicator of the patient response to MTX treatment.

**Data availability**

**Underlying data**

Figshare: Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study https://doi.org/10.6084/m9.figshare.18079136.
Acknowledgments
The protocol of the study was approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia and Dr Cipto Mangunkusumo General Hospital (KET-1144/UN2.F1/ETIK/PPM.00.02/2020). All patients provided written informed consent prior to participate in this study. All works were conducted in accordance with The Code of the World Medical Association (Declaration of Helsinki).

Acknowledgments
We would like thanks to all patients participated in this study and all staff at Rheumatology Polyclinic of Dr Cipto Mangunkusumo General Hospital, Jakarta.

References

1. Smolen JS, Landewe R, Breedveld FC, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar; 73(3): 492–509. PubMed Abstract | Publisher Full Text | Free Full Text
2. Funk RS, van Haandel L, Becker ML, Leeder JS: Low-dose methotrexate results in the selective accumulation of aminomimidazole carboxamide ribotide in an erythroblastoid cell line. J Pharmacol Exp Ther. 2013 Oct; 347(1): 154–163. PubMed Abstract | Publisher Full Text | Free Full Text
3. Singh JA, Saag KG, Bridges SL Jr., et al.: 2013 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan; 68(1): 1–26. PubMed Abstract | Publisher Full Text
4. Smolen JS, Landewe R, Bijlsma J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun; 76(6): 960–977. PubMed Abstract | Publisher Full Text
5. Dervieux T, Zablocki R, Kremer J: Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford). 2010 Dec; 49(12): 2337–2345. PubMed Abstract | Publisher Full Text
6. Mikkelsen TS, Thorn CF, Yang J., et al.: PharmGKB summary: methotrexate pathway. Pharmagenet Genomics. 2011 Oct; 21(10): 679–686. PubMed Abstract | Publisher Full Text | Free Full Text
7. Woolf RT, West SL, Arenas-Hernandez M, et al.: Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study. Br J Dermatol. 2012 Jul; 167(1): 165–173. PubMed Abstract | Publisher Full Text | Free Full Text
8. Danila MI, Hughes LB, Brown EE, et al.: Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?. Curr Rheumatol Rep. 2010 Oct; 12(5): 342–347. PubMed Abstract | Publisher Full Text | Free Full Text
9. de Rotte MC, den Boer E, de Jong PH, et al.: Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015 Feb; 74(2): 408–414. PubMed Abstract | Publisher Full Text | Free Full Text
10. Stamp LK, O'Donnell JL, Chapman PT, et al.: Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010 Feb; 62(2): 359–368. PubMed Abstract | Publisher Full Text
11. Hobli EL, Jliba M, Erlacher L., et al.: A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2012 Mar-Apr; 30(2): 156–163. PubMed Abstract
12. Guo Q, Wang Y, Xu D., et al.: Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018; 6: 15. PubMed Abstract | Publisher Full Text | Free Full Text
13. Kusner I: C-reactive protein in rheumatology. Arthritis Rheum. 1991 Aug; 34(8): 1065–1068. PubMed Abstract
14. Aletaha D, Neogi T, Silman AJ, et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9): 2569–2581. PubMed Abstract | Publisher Full Text
15. Wells G, Becker JC, Teng J, et al.: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009 Jun; 68(6): 954–960. PubMed Abstract | Publisher Full Text | Free Full Text
16. Aletaha D, Ward MM, Machold KP, et al.: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005 Sep; 52(9): 2625–2636. PubMed Abstract | Publisher Full Text | Free Full Text
17. Takahashi C, Kanoeko Y, Okano Y, et al.: Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. JIMD Rep. 2017; 3(1): e000363. PubMed Abstract | Publisher Full Text | Free Full Text
18. Taylor PC, Balsa Criado A, Mongey AB, et al.: How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?: MTX in the Treat-to-Target Strategy. J Clin Med. 2019 Apr 15; 8(4): Epub 20190415. PubMed Abstract | Free Full Text | Publisher Full Text
19. Smolen JS, Aletaha D, Bijlsma JW, et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010 Apr; 69(4): 631–637. PubMed Abstract | Free Full Text | Publisher Full Text
20. Raimondi MV, Randazzo O, La Franca M, et al.: DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents. Molecules. 2019 Mar 22; 24(5): Epub 20190322. PubMed Abstract | Publisher Full Text | Free Full Text

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Reporting guidelines
Figshare: STROBE checklist for ‘Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study’, https://doi.org/10.6084/m9.figshare.18743006.

Evaluating the Past for Discovering Novel Anticancer Agents.
21. Friedman B, Cronstein B: Methotrexate mechanism in treatment of rheumatoid arthritis. *Joint Bone Spine* 2019 May; 86(3): 301–307. PubMed Abstract | Publisher Full Text | Free Full Text

22. Chan ES, Cronstein BN: Mechanisms of action of methotrexate. *Bull Hosp Jt Dis (2013)* 2013; 71 Suppl 1: S5–S8. PubMed Abstract

23. Yang JY, Webster-Clark M, Lund JL, et al.: Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. *Gastrointest Endosc.* 2019 Sep; 90(3): 360–369. PubMed Abstract | Free Full Text

24. den Boer E, de Rotte MC, Pluijm SM, et al.: Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. *J Rheumatol.* 2014 Nov; 41(11): 2167–2178. PubMed Abstract | Publisher Full Text
Open Peer Review

Current Peer Review Status: ✔️ ? ?

Version 1

Reviewer Report 02 March 2022

https://doi.org/10.5256/f1000research.120131.r123624

© 2022 Emran T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Talha Bin Emran
Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh

Title: Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study

Minor comments:
Although the article has scientific rigor, several minor flows need to be improved before publication:

1. The abstract section is unsuitable—no focus point in the abstract section.

2. "Nevertheless, a prospective study with a higher number of patients is needed to confirm this finding." Is this necessary?

3. Authors are suggested to use the full form when used for the first time throughout the manuscript.

4. The aim of the study should be written as the last paragraph of the introduction.

7. MTX treatment and follow-up: How was this selected?

8. Receiver Operating Characteristics (ROC) analysis: Please describe in further detail.

9. "Further analysis using the ROC curve showed that MTX-PG3 level..." needs more insights with relevant references.

10. Presentation of figures is good.

11. Figure legends are appropriate and self-explanatory.

12. The conclusion needs to address future perspectives.
13. Spacing, punctuation marks, grammar, and spelling errors should be reviewed thoroughly.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

*Competing Interests:* No competing interests were disclosed.

*Reviewer Expertise:* Public health, Immunology, Natural Product Chemistry

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 23 February 2022

https://doi.org/10.5256/f1000research.120131.r123627

© 2022 Frediansyah A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andri Frediansyah
Research Division for Natural Product Technology, Indonesian Institute of Sciences (LIPI), Wonosari, Indonesia

The researchers looked at 34 people with rheumatoid arthritis (RA) to see if there was a link between MTX-PG levels and how active their RA was. There were two women and 32 men in the study. The subject matter is of general interest, and the study yields useful information. There are, however, a few issues that should be addressed:
1) Please specify the date, duration, and months of the experiment.

2) Please verify the following statement: "low disease activity, <3.2–5.1". Is this correct?

3) The methods section is unclear. Please describe it in detail. Is there a particular type of blood (whole blood, red, or white blood cells) that you used in the study? Additionally, please provide detailed information about the centrifugation parameters, such as time, temperature, and g-force/RCF (g). Prior to analysis, is the blood subjected to any special treatment?

4) Please rewrite the section on chromatography measurement and analysis in detail. Include the HPLC specification and brand; column details (including particle size, pore size, inner diameter, and length); ammonium hydrochloride concentration and pH; solvent B composition (or A, if any); and the reference you cited.

5) Did you combine ammonium bicarbonate and ammonium chloride, and if so, in what proportion? Which detector (UV/CAD/MS) did you use? If UV/DAD, at what wavelength did you adjust the detector?

6) Please specify the brand of the MTX-PG3 standard and the R2 (nmol) value of the standard you used.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmaco Biology/Analytical Chemistry

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Slobodan M. Janković
Faculty of Medical Sciences, Department of Pharmacy, University of Kragujevac, Kragujevac, Serbia

The authors made an observational study trying to correlate MTX PG levels with disease activity of RA (as measured by a clinical score). The topic is of general interest, and the study brings results with practical significance. The manuscript is well written, and merits acceptance for publication. However, there are a few issues that should be corrected:

1. In the Methods section the authors should state precisely how they measures the MTX PG levels in erythrocytes. As it is written now, it is not clear whether the MTX PG levels were measured in erythrocytes or in full blood.

2. Number of patients is small, so it is critical that statistical methods were used properly. The authors should state whether assumptions of multivariate logistic regression were met. Also, what was the categorical outcome used as dependent variable of the regression? Finally, quality of the regression model should be stated (Hosmer Lemeshow test, Cox and Snellen...).

3. Something should be said about adherence of the patients to the therapy. Was there any method used to check for adherence? If not, mention this in the Limitation paragraph.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com